Brokerages forecast that Nu Skin Enterprises, Inc. (NYSE:NUS) will report earnings per share (EPS) of $1.16 for the current quarter, Zacks reports. Two analysts have issued estimates for Nu Skin Enterprises’ earnings, with the lowest EPS estimate coming in at $1.09 and the highest estimate coming in at $1.20. Nu Skin Enterprises posted earnings per share of $0.79 in the same quarter last year, which indicates a positive year over year growth rate of 46.8%. The company is expected to issue its next quarterly earnings results on Thursday, February 15th.

According to Zacks, analysts expect that Nu Skin Enterprises will report full year earnings of $3.23 per share for the current financial year. For the next fiscal year, analysts forecast that the company will post earnings of $3.60 per share, with EPS estimates ranging from $3.36 to $4.02. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Nu Skin Enterprises.

Nu Skin Enterprises (NYSE:NUS) last announced its earnings results on Wednesday, November 1st. The company reported $0.76 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.76. Nu Skin Enterprises had a return on equity of 22.38% and a net margin of 6.97%. The business had revenue of $563.70 million during the quarter, compared to analysts’ expectations of $562.70 million. During the same quarter last year, the business posted $0.98 earnings per share. The company’s quarterly revenue was down 6.7% on a year-over-year basis.

Several research analysts recently weighed in on the company. Zacks Investment Research cut Nu Skin Enterprises from a “hold” rating to a “sell” rating in a research note on Wednesday, December 20th. ValuEngine upgraded Nu Skin Enterprises from a “hold” rating to a “buy” rating in a research report on Sunday, December 31st. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. Nu Skin Enterprises has an average rating of “Hold” and a consensus price target of $63.14.

In related news, insider Joseph Y. Chang sold 36,503 shares of the stock in a transaction on Friday, November 10th. The stock was sold at an average price of $62.24, for a total value of $2,271,946.72. Following the completion of the transaction, the insider now owns 66,563 shares in the company, valued at approximately $4,142,881.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Steven Lund sold 8,977 shares of the firm’s stock in a transaction dated Wednesday, December 27th. The stock was sold at an average price of $70.04, for a total value of $628,749.08. Following the sale, the chairman now owns 4,769 shares of the company’s stock, valued at $334,020.76. The disclosure for this sale can be found here. Insiders sold a total of 227,709 shares of company stock valued at $15,228,036 in the last quarter. 5.20% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in NUS. Old Mutual Global Investors UK Ltd. boosted its position in Nu Skin Enterprises by 179,062.6% during the 3rd quarter. Old Mutual Global Investors UK Ltd. now owns 503,447 shares of the company’s stock worth $30,951,000 after acquiring an additional 503,166 shares during the period. Skandinaviska Enskilda Banken AB publ boosted its position in Nu Skin Enterprises by 462.8% during the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 570,100 shares of the company’s stock worth $35,050,000 after acquiring an additional 468,800 shares during the period. Prudential Financial Inc. boosted its position in Nu Skin Enterprises by 826.4% during the 3rd quarter. Prudential Financial Inc. now owns 374,549 shares of the company’s stock worth $23,027,000 after acquiring an additional 334,120 shares during the period. UBS Asset Management Americas Inc. boosted its position in Nu Skin Enterprises by 751.6% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 309,983 shares of the company’s stock worth $19,479,000 after acquiring an additional 273,581 shares during the period. Finally, Principal Financial Group Inc. boosted its position in Nu Skin Enterprises by 84.7% during the 2nd quarter. Principal Financial Group Inc. now owns 420,755 shares of the company’s stock worth $26,440,000 after acquiring an additional 192,958 shares during the period. Hedge funds and other institutional investors own 77.50% of the company’s stock.

Shares of Nu Skin Enterprises (NYSE NUS) traded up $0.38 during mid-day trading on Friday, reaching $68.79. The company had a trading volume of 207,440 shares, compared to its average volume of 320,848. Nu Skin Enterprises has a fifty-two week low of $47.10 and a fifty-two week high of $70.27. The company has a market capitalization of $3,601.79, a PE ratio of 25.20, a P/E/G ratio of 2.23 and a beta of 1.56. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.78 and a quick ratio of 1.18.

TRADEMARK VIOLATION NOTICE: This news story was reported by Marea Informative and is the property of of Marea Informative. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at https://www.mareainformativa.com/2018/01/29/brokerages-anticipate-nu-skin-enterprises-inc-nus-to-announce-1-16-eps-updated-updated-updated.html.

Nu Skin Enterprises Company Profile

Nu Skin Enterprises, Inc is a direct selling company that develops and distributes personal care products and nutritional supplements, and a range of other products and services. The Company offers anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands. The Nu Skin brand offers a range of products, including ageLOC Me customized skin care system, ageLOC Spa systems and ageLOC Transformation anti-aging skin care system.

Get a free copy of the Zacks research report on Nu Skin Enterprises (NUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.